Peter J Sciavolino, PhD

Clinical trial findings have implications for expanding the use of genomic testing—and thereby potentially increasing treatment options—for the younger lung cancer population.

As clinical experience grows with new agents, combinations, and sequences of therapy, the use of molecular profiling in metastatic melanoma is likely to become an essential means of choosing among treatment options.

Between immunotherapies and targeted therapies-both of which certainly offer bold new opportunities for disease control over cytotoxic therapies-which treatment modality do oncologists think has had the greatest overall impact on NSCLC treatment?

Pierre M. Gholam, MD, discusses managing elderly patients with advanced HCC, including current practices and emerging strategies.

Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.

Although prognostic biomarkers have become increasingly important in the treatment of many types of cancer, no such markers have yet been identified and validated for thyroid cancer.

Aprepitant is significantly more effective than a comparator placebo-added regimen in preventing CINV in children, with benefits seen across all phases of treatment.

Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline with placebo in patients with non-small cell lung cancer.

A single oral dose of rolapitant was found to be effective, safe, and long-lasting for the prevention of CINV in patients whose cancer was being treated with either highly or moderately emetogenic chemotherapy.

Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based moderately emetogenic chemotherapy when compared with a longer duration of dexamethasone.

For the prevention of nausea and vomiting after the first day of cisplatin-based chemotherapy, both aprepitant and metoclopramide when used in combination with dexamethasone were found to be similarly effective.